JPH08510715A - フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤 - Google Patents
フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤Info
- Publication number
- JPH08510715A JPH08510715A JP6512452A JP51245294A JPH08510715A JP H08510715 A JPH08510715 A JP H08510715A JP 6512452 A JP6512452 A JP 6512452A JP 51245294 A JP51245294 A JP 51245294A JP H08510715 A JPH08510715 A JP H08510715A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- fibronectin
- amino acid
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 161
- 108010067306 Fibronectins Proteins 0.000 title claims abstract description 127
- 102000021124 collagen binding proteins Human genes 0.000 title claims abstract description 11
- 108091011142 collagen binding proteins Proteins 0.000 title claims abstract description 11
- 102100037362 Fibronectin Human genes 0.000 title claims 9
- 239000003112 inhibitor Substances 0.000 title description 9
- 230000027455 binding Effects 0.000 claims abstract description 91
- 108060008245 Thrombospondin Proteins 0.000 claims abstract description 52
- 102000002938 Thrombospondin Human genes 0.000 claims abstract description 51
- 229920000159 gelatin Polymers 0.000 claims abstract description 48
- 239000008273 gelatin Substances 0.000 claims abstract description 48
- 108010010803 Gelatin Proteins 0.000 claims abstract description 46
- 235000019322 gelatine Nutrition 0.000 claims abstract description 46
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 46
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 8
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- FBTYOQIYBULKEH-ZFWWWQNUSA-N His-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CNC=N1 FBTYOQIYBULKEH-ZFWWWQNUSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- 102000029816 Collagenase Human genes 0.000 claims 1
- 108060005980 Collagenase Proteins 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 229960002424 collagenase Drugs 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 abstract description 118
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 47
- 102000008186 Collagen Human genes 0.000 abstract description 17
- 108010035532 Collagen Proteins 0.000 abstract description 17
- 229920001436 collagen Polymers 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 230000003993 interaction Effects 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 230000021164 cell adhesion Effects 0.000 abstract description 8
- 230000001419 dependent effect Effects 0.000 abstract description 5
- 210000002889 endothelial cell Anatomy 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 46
- 108010088429 glycyl-glycyl-tryptophyl-seryl-histidyl-tryptophan Proteins 0.000 description 46
- 230000005764 inhibitory process Effects 0.000 description 22
- WJKXMMKXXDAANJ-DZUOILHNSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 WJKXMMKXXDAANJ-DZUOILHNSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000012422 Collagen Type I Human genes 0.000 description 9
- 108010022452 Collagen Type I Proteins 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 201000008275 breast carcinoma Diseases 0.000 description 7
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- HZKLCOYAVAAQRD-VGMNWLOBSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxyethyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N HZKLCOYAVAAQRD-VGMNWLOBSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- OVXIMRGEBNSORH-UHFFFAOYSA-N 2-[[2-[2-[[2-[[1-[1-[5-amino-2-[[2-amino-3-(1h-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylp Chemical compound CCC(C)C(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C1N(C(=O)C(CCC(N)=O)NC(=O)C(N)CC=2C3=CC=CC=C3NC=2)CCC1 OVXIMRGEBNSORH-UHFFFAOYSA-N 0.000 description 1
- POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 230000010556 Heparin Binding Activity Effects 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- RVKIPWVMZANZLI-ZFWWWQNUSA-N Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-ZFWWWQNUSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108010086780 arginyl-glycyl-aspartyl-alanine Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.フィブロネクチンのゼラチン-結合性ドメインについての特異的な結合ア フィニティーを有するペプチドであって、少なくとも5のアミノ酸を含んで成り 、そして配列HisTrp及び少なくとも1の他のトリプトファン残基を含むようなペ プチド。 2.ペプチドが配列XaaHisTrp{ここで、Xaaがセリン、トレオニン及びアラニ ンから成るアミノ酸の群から選ばれる。}を含んで成る、請求項1に記載のペプ チド。 3.ペプチドが5〜30アミノ酸残基を含んで成る、請求項1に記載のペプチド 。 4.ペプチドが6〜20アミノ酸を含んで成る、請求項1に記載のペプチド。 5.アミノ-末端N-アセチル及びカルボキシル-末端アミドをさらに含んで成る 、請求項1に記載のペプチド。 6.フィブロネクチンのゼラチン-結合性ドメインについての特異的な結合ア フィニティーを有するペプチドであって、30までのアミノ酸をもち、そして以下 の配列(A): Xa-Xb-His-Trp-Xc {ここで、XaがH又は1〜27アミノ酸のアミノ酸配列であり、Xbがセリン、アラ ニン、トリプトファン、又はトレオニンであり、そしてXcがOH、NH2又は1〜27 アミノ酸のアミノ酸配列であり、そしてXa及びXbの中の少なくとも1が配列(A )内にTrpから3アミノ酸残基内に位置するトリプトファンを含む。}を含んで 成るようなペプチド。 7.Xaがアミノ酸残基394-420を含む連続的に生じたトロンボスポンジン・ア ミノ酸配列から得られた1〜27アミノ酸のアミノ酸配 列であり、Xbがセリン、アラニン又はトレオニンであり、そしてXcがアミノ酸残 基424-450を含む連続的に生じたヒト・トロンボスポンジン・アミノ酸配列から 得られた1〜27アミノ酸のアミノ酸配列である、請求項6に記載のペプチド。 8.ペプチドが配列番号1、配列番号2、配列番号3、配列番号4、配列番号 5、配列番号6、配列番号7及び配列番号8から成る群から選ばれた配列をもつ 、請求項1に記載のペプチド。 9.ペプチドがGlyGlyTrpXaaHisTrp{ここで、Xaaがセリン、トレオニン及び アラニンから成るアミノ酸の群から選ばれる。}を含んで成る、請求項1に記載 のペプチド。 10.Xaaがアラニンである、請求項4に記載のペプチド。 11.Xaaがセリンである、請求項4に記載のペプチド。 12.フィブロネクチン又は他の関連コラーゲン-結合性タンパク質に結合す るための医薬組成物であって、少なくとも1の請求項1に記載のペプチドの有効 量及び医薬として許容される賦形剤又は担体を含んで成る医薬組成物。 13.有効量のペプチドが配列番号1、配列番号2、配列番号3、配列番号4 、配列番号5、配列番号6、配列番号7及び配列番号8から成る群から選ばれた 配列をもつペプチドである、請求項12に記載の医薬組成物。 14.ペプチドがフィブロネクチンのゼラチン-結合性ドメインについての特 異的な結合アフィニティーを有するペプチドであって、そのペプチドが30までの アミノ酸をもち、そして以下の配列(A): Xa-Xb-His-Trp-Xc {ここで、XaがH又は1〜27アミノ酸のアミノ酸配列であり、Xbがセリン、アラニ ン、トリプトファン、又はトレオニンであり、そしてXcがOH、NH2又は1〜27ア ミノ酸のアミノ酸配列であり、そして Xa及びXbの中の少なくとも1が配列(A)内にTrpから3アミノ酸残基内に位置す るトリプトファンを含む。}を含んで成るような、請求項12に記載の医薬組成 物。 15.Xaがアミノ酸残基394-420を含む連続的に生じたトロンボスポンジン・ アミノ酸配列から得られた1〜27アミノ酸のアミノ酸配列であり、Xbがセリン、 アラニン又はトレオニンであり、そしてXcがアミノ酸残基424-450を含む連続的 に生じたヒト・トロンボスポンジン・アミノ酸配列から得られた1〜27アミノ酸 のアミノ酸配列である、請求項14に記載の医薬組成物。 16.フィブロネクチン又は他の関連コラーゲン-結合性タンパク質に結合す るための医薬組成物であって、少なくとも1の請求項4に記載のペプチドの有効 量及び医薬として許容される賦形剤又は担体を含んで成る医薬組成物。 17.ペプチドが配列番号1に記載の配列をもつペプチドである、請求項13 に記載の医薬組成物。 18.治療の必要な患者においてフィブロネクチン又は他の関連コラーゲン- 結合性タンパク質に結合するための方法であって、請求項12に記載の医薬組成 物の有効量をそのような患者に投与することを含んで成る方法。 19.フィブロネクチン、マトリックス・メタロプロテイナーゼ-2、マトリッ クス・メタロプロテイナーゼ-9又は他の関連コラーゲン-結合性タンパク質に結 合するための請求項18に記載の方法であって、そのペプチドが配列番号1、配 列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7及び 配列番号8から成る群から選ばれた配列をもつペプチドであるような方法。 20.治療の必要な患者においてコラゲナーゼ及びフィブロネクチンに相同な 他のプロテアーゼの酵素活性を阻害する方法であって、 医薬として許容される賦形剤又は担体内に含まれる少なくとも1のペプチドの有 効量をそのような患者に投与することを含んで成り、そのペプチドが配列番号1 、配列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7 及び配列番号8から成る群から選ばれた配列をもつペプチドであるような方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US973,235 | 1992-11-10 | ||
US07/973,235 US5491130A (en) | 1992-11-10 | 1992-11-10 | Peptide inhibitors of fibronectin and related collagen-binding proteins |
PCT/US1993/011104 WO1994011395A1 (en) | 1992-11-10 | 1993-11-09 | Peptide inhibitors of fibronectin and related collagen-binding proteins |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005282907A Division JP2006028195A (ja) | 1992-11-10 | 2005-09-28 | フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08510715A true JPH08510715A (ja) | 1996-11-12 |
JP3789931B2 JP3789931B2 (ja) | 2006-06-28 |
Family
ID=25520653
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51245294A Expired - Fee Related JP3789931B2 (ja) | 1992-11-10 | 1993-11-09 | フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤 |
JP2005282907A Pending JP2006028195A (ja) | 1992-11-10 | 2005-09-28 | フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005282907A Pending JP2006028195A (ja) | 1992-11-10 | 2005-09-28 | フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5491130A (ja) |
EP (1) | EP0669937B1 (ja) |
JP (2) | JP3789931B2 (ja) |
AT (1) | ATE183196T1 (ja) |
AU (1) | AU683234B2 (ja) |
CA (1) | CA2148383A1 (ja) |
DE (1) | DE69326016T2 (ja) |
WO (1) | WO1994011395A1 (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT690720E (pt) * | 1993-03-12 | 2001-12-28 | Xoma Technology Ltd | Utilizacoes terapeuticas de produtos de proteina bactericida indutora de permeabilidade |
JP3192067B2 (ja) * | 1995-10-09 | 2001-07-23 | 科学技術振興事業団 | ペプチドとコラーゲン収縮阻害剤 |
US6288214B1 (en) | 1996-05-16 | 2001-09-11 | Texas A&M University Systems | Collagen binding protein compositions and methods of use |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US20060025348A1 (en) * | 1997-05-28 | 2006-02-02 | Pilon Aprile L | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
US20020169108A1 (en) * | 1997-05-28 | 2002-11-14 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
US20060281681A1 (en) * | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
GB9714276D0 (en) | 1997-07-08 | 1997-09-10 | Univ Dundee | Peptides and related compounds |
US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
US6716963B1 (en) | 1998-05-22 | 2004-04-06 | Abbott Laboratories | Peptide antiangiogenic drugs |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
GB9903408D0 (en) * | 1999-02-15 | 1999-04-07 | Oxford Biomedica Ltd | Peptides |
AU777844B2 (en) * | 1999-04-16 | 2004-11-04 | Children's Medical Center Corporation | Adhesion modulatory peptides and methods for use |
CN1301723A (zh) * | 1999-12-27 | 2001-07-04 | 上海博德基因开发有限公司 | 一种新的多肽——纤维结合蛋白类型ii10和编码这种多肽的多核苷酸 |
EP1259548A1 (en) * | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
US6309454B1 (en) | 2000-05-12 | 2001-10-30 | Johnson & Johnson Medical Limited | Freeze-dried composite materials and processes for the production thereof |
AU1218202A (en) * | 2000-09-07 | 2002-03-22 | Schering Ag | Receptor in the ED<sub>b</sub> fibronectin domain |
EP1224943A1 (en) * | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
WO2002074324A1 (en) * | 2001-03-15 | 2002-09-26 | The Texas A & M University System | Collagen-binding adhesin from staphylococcus epidermidis and method of use |
CA2520604A1 (en) * | 2003-05-09 | 2004-11-25 | Research Development Foundation | Insertion of furin protease cleavage sites in membrane proteins and uses thereof |
DK2299275T3 (en) * | 2004-07-30 | 2018-05-07 | Adeza Biomedical Corp | Classification of oncofetal fetronectin level for pregnancy-related indications |
US8253725B2 (en) * | 2007-12-28 | 2012-08-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and system for generating surface models of geometric structures |
EP2303308A4 (en) | 2008-05-13 | 2012-11-07 | Clarassance Inc | HUMAN RECOMBINANT PROTEIN CC10 AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF NASAL RHINITIS |
EP2340034B2 (en) * | 2008-08-07 | 2019-02-13 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
US9168285B2 (en) | 2009-10-15 | 2015-10-27 | Therabron Therapeutics, Inc. | Recombinant human CC10 protein for treatment of influenza and ebola |
NZ599511A (en) | 2009-10-15 | 2014-06-27 | Clarassance Inc | Recombinant human cc10 protein for treatment of influenza |
US10407665B2 (en) | 2012-04-09 | 2019-09-10 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods for generation of pluripotent and multipotent cells |
WO2014028862A1 (en) | 2012-08-17 | 2014-02-20 | Cornell University | Use of dna in circulating exosomes as a diagnostic marker for metastasic disease |
AU2014244083B2 (en) | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
WO2015153732A2 (en) | 2014-04-01 | 2015-10-08 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
FR3024364B1 (fr) | 2014-07-31 | 2016-09-02 | Neuronax | Oligopeptides particuliers comme medicaments anti-angiogeniques |
US11397182B2 (en) | 2014-10-07 | 2022-07-26 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
PE20211279A1 (es) | 2018-10-23 | 2021-07-19 | Dragonfly Therapeutics Inc | Proteinas heterodimericas fusionadas con fc |
JP2023522972A (ja) | 2020-04-22 | 2023-06-01 | ドラゴンフライ セラピューティクス, インコーポレイテッド | ヘテロ二量体Fc融合タンパク質のための製剤、投薬量レジメン、及び製造工程 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1001013A4 (fr) * | 1987-10-22 | 1989-06-13 | Icp Internat Inst Of Cellular | Derives de synergimycines de types a et b, procede pour leur preparation et utilisation de ceux-ci. |
US5190918A (en) * | 1990-02-22 | 1993-03-02 | W. R. Grace & Co.-Conn. | Peptide fragments and analogs of thrombospondin and methods of use |
US5200397A (en) * | 1990-02-22 | 1993-04-06 | W. R. Grace & Co.-Conn. | Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity |
US5357041A (en) * | 1991-12-06 | 1994-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin |
-
1992
- 1992-11-10 US US07/973,235 patent/US5491130A/en not_active Expired - Fee Related
-
1993
- 1993-11-09 JP JP51245294A patent/JP3789931B2/ja not_active Expired - Fee Related
- 1993-11-09 EP EP94902266A patent/EP0669937B1/en not_active Expired - Lifetime
- 1993-11-09 CA CA002148383A patent/CA2148383A1/en not_active Abandoned
- 1993-11-09 WO PCT/US1993/011104 patent/WO1994011395A1/en active IP Right Grant
- 1993-11-09 DE DE69326016T patent/DE69326016T2/de not_active Expired - Fee Related
- 1993-11-09 AU AU56695/94A patent/AU683234B2/en not_active Ceased
- 1993-11-09 AT AT94902266T patent/ATE183196T1/de active
-
1995
- 1995-06-05 US US08/462,720 patent/US5849701A/en not_active Expired - Fee Related
-
2005
- 2005-09-28 JP JP2005282907A patent/JP2006028195A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69326016D1 (de) | 1999-09-16 |
JP2006028195A (ja) | 2006-02-02 |
ATE183196T1 (de) | 1999-08-15 |
CA2148383A1 (en) | 1994-05-26 |
EP0669937A1 (en) | 1995-09-06 |
AU683234B2 (en) | 1997-11-06 |
JP3789931B2 (ja) | 2006-06-28 |
WO1994011395A1 (en) | 1994-05-26 |
EP0669937B1 (en) | 1999-08-11 |
US5491130A (en) | 1996-02-13 |
AU5669594A (en) | 1994-06-08 |
US5849701A (en) | 1998-12-15 |
DE69326016T2 (de) | 2000-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08510715A (ja) | フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤 | |
WO1994011395A9 (en) | Peptide inhibitors of fibronectin and related collagen-binding proteins | |
US5192746A (en) | Cyclic cell adhesion modulation compounds | |
JP5384342B2 (ja) | 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド | |
AU601801B2 (en) | Anticoagulant peptides | |
WO1994015958A2 (en) | Peptide inhibitors of cell adhesion | |
AU8239987A (en) | Thrombin derived polypeptides; compositions and methods for use | |
EP0478101B1 (en) | Therapeutic use of peptides having thrombospondin-like activity | |
BG65065B1 (bg) | Пептидни антиангиогенни лекарствени средства | |
JPH03118331A (ja) | 環状フイブリノーゲンレセプター拮抗薬 | |
JPH07501808A (ja) | ヒトトロンボスポンジンの1型繰返体からのヘパリン−およびスルファチド結合ペプチド | |
EP0514721A1 (en) | Peptides having thrombospondin-like activity and their therapeutic use | |
JP3621099B2 (ja) | 骨原性成長オリゴペプチドおよびそれを含む医薬組成物 | |
US6339062B1 (en) | Retroinverso polypeptides that mimic or inhibit thrombospondin activity | |
CA2610496A1 (en) | Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 | |
JP2003514920A (ja) | 抗血管新生活性を有するn−アルキル化ペプチド | |
US5721210A (en) | Cyclic cell adhesion modulation compounds | |
AU773862B2 (en) | Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof | |
AU642487B2 (en) | Neutrophil stimulating peptides | |
MXPA04007170A (es) | Peptidos sinteticos y usos de los mismos para la prevencion y la terapia de metastasis e invasion de cancer. | |
JPH03284700A (ja) | 機能性ポリペプチド | |
Zakutskii et al. | Functional arginine-containing amino acid sequences in peptides and proteins | |
WO2007048102A2 (en) | Angio-inhibitory peptides derived from human timp-2 | |
JP2002532400A (ja) | 高分子キニノゲンドメイン3ペプチド類似体による血管形成の阻害 | |
WO2014075137A1 (en) | Peptides incorporating amino-substituted lactams for treatment of retinopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050928 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060330 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |